Cutaneous squamous cell carcinoma in two pediatric lung transplant patients on prolonged voriconazole treatment

Pediatric Transplantation

Volumn 18, Issue 6, 2014, Pages

  Wong, Jackson Y ^a   Kuzel, Paul ^a   Mullen, John ^a   Lien, Dale ^a   Mahmood, Muhammad ^a   Conrad, Carol ^b   Fiorillo, Loretta ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b STANFORD UNIVERSITY   (United States)

Author keywords

lung transplantation; malignancy; organ transplantation; pediatrics; skin cancer; squamous cell carcinoma; voriconazole

Indexed keywords

VORICONAZOLE; ANTIFUNGAL AGENT;

ACTINIC KERATOSIS; ADOLESCENT; ARTICLE; ASPERGILLOSIS; CASE REPORT; CAUCASIAN; CHILD; CHRONIC DRUG ADMINISTRATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; LUNG TRANSPLANTATION; MALE; NONHUMAN; PHOTOSENSITIVITY; PHOTOTOXICITY; RARE DISEASE; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SKIN CARCINOMA; SYSTEMIC MYCOSIS; CHEMICALLY INDUCED; IMMUNOLOGY; LUNG DISEASES, FUNGAL; PHOTOSENSITIVITY DISORDER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ANTIFUNGAL AGENTS; CARCINOMA, SQUAMOUS CELL; CHILD; FEMALE; HUMANS; LUNG DISEASES, FUNGAL; LUNG TRANSPLANTATION; MALE; PHOTOSENSITIVITY DISORDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SKIN NEOPLASMS; VORICONAZOLE;

EID: 84906080626     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12320     Document Type: Article

References (47)

1. Luong ML, Chaparro C, Stephenson A, et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation 2014: 97: 351-357.
2. Singh N, Husain S, AST Infectious Diseases Community of Practice. Aspergillosis in solid organ transplantation. Am J Transplant 2013: 13 (Suppl 4): 228-241.
3. Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012: 65: 453-464.
4. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011: 17: 1855-1864.
5. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010: 12: 220-229.
6. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009: 9: 1903-1911.
7. Danziger-Isakov LA, Worley S, Arrigain S, et al. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J Heart Lung Transplant 2008: 27: 655-661.
8. Arthurs SK, Eid AJ, Deziel PJ, et al. The impact of invasive fungal diseases on survival after lung transplantation. Clin Transplant 2010: 24: 341-348.
9. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation-a world-wide survey. Am J Transplant 2011: 11: 361-366.
10. Ghannoum MA, Kuhn DM,. Voriconazole-better chances for patients with invasive mycoses. Eur J Med Res 2002: 7: 242-256.
11. Cooper JZ, Brown MD,. Special concern about squamous cell carcinoma of the scalp in organ transplant recipients. Arch Dermatol 2006: 142: 755-758.
12. Feist A, Lee R, Osborne S, Lane J, Yung G,. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant 2012: 31: 1177-1181.
13. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O,. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008: 46: 201-211.
14. Ibrahim SF, Singer JP, Arron ST,. Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole. Dermatol Surg 2010: 36: 1752-1755.
15. Zwald FO, Spratt M, Lemos BD, et al. Duration of voriconazole exposure: An independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012: 38: 1369-1374.
16. McCarthy KL, Playford EG, Looke DF, Whitby M,. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007: 44: e55-e56.
17. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010: 62: 31-37.
18. Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010: 29: 1240-1244.
19. Epaulard O, Leccia MT, Blanche S, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect 2011: 41: 639-645.
20. Haylett AK, Felton S, Denning DW, Rhodes LE,. Voriconazole-induced photosensitivity: Photobiological assessment of a case series of 12 patients. Br J Dermatol 2013: 168: 179-185.
21. Elbaum DJ, Cowen EW,. Voriconazole-associated phototoxic effects and lentigo formation in an African American man. Arch Dermatol 2012: 148: 965-966.
22. Bernhard S, Kernland Lang K, Ammann RA, et al. Voriconazole-induced phototoxicity in children. Pediatr Infect Dis J 2012: 31: 769-771.
23. Division of Special Pathogen and Immunologic Drug Products, Center for Drug Evalaution and Research, Food and Drug Administration. Background document for the antiviral drug products advisory committee meeting. October 4, 2001.
24. Simard JF, Baecklund E, Kinch A, et al. Pediatric organ transplantation and risk of premalignant and malignant tumors in Sweden. Am J Transplant 2011: 11: 146-151.
25. Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004: 4: 796-802.
26. Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007: 83: 1330-1336.
27. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation. J Heart Lung Transplant 2006: 25: 745-755.
28. Liu M, Worley S, Mallory GB, et al. Fungal infections in pediatric lung transplant recipients: Colonization and invasive disease. J Heart Lung Transplant 2009: 28: 1226-1230.
29. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: Hepatotoxicity and effectiveness. Am J Transplant 2009: 9: 2085-2091.
30. Neoh CF, Snell GI, Levvey B, et al. Pre-emptive treatment with voriconazole in lung transplant recipients. Transpl Infect Dis 2013: 15: 344-353.
31. Capitano B, Potoski BA, Husain S, et al. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006: 50: 1878-1880.
32. Heng SC, Snell GI, Levvey B, et al. Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients. Antimicrob Agents Chemother 2013: 57: 4581-4583.
33. Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother 2010: 54: 4424-4431.
34. Berge M, Guillemain R, Boussaud V, et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis 2009: 11: 211-219.
35. Berge M, Guillemain R, Tregouet DA, et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 2011: 67: 253-260.
36. Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: Factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012: 56: 2371-2377.
37. Tofte N, Jensen C, Tvede M, Andersen CB, Carlsen J, Iversen M,. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: A retrospective study of 147 patients. Scand J Infect Dis 2012: 44: 835-841.
38. McLaughlin JM, Equils O, Somerville KT, et al. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. Transpl Infect Dis 2013: 15: 329-343.
39. Bernhard S, Kernland LK, Ammann RA, et al. Voriconazole-induced phototoxicity in children. Pediatr Infect Dis J 2012: 31: 769-771.
40. Thaunat O, Morelon E,. Cancer and immunosuppression: Pro- and antitumoral effects of immunosuppressive drugs. Nephrol Ther 2005: 1: 23-30.
41. Taylor AE, Shuster S,. Skin cancer effective renal transplantation: The causal role of azathioprine. Acta Derm Venereol 1992: 72: 115-119.
42. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012: 31: 694-699.
43. Rondeau S, Couderc L, Dominique S, et al. High frequency of voriconazole-related phototoxicity in cystic fibrosis patients. Eur Respir J 2012: 39: 782-784.
44. Markantonis SL, Katelari A, Pappa E, Doudounakis S,. Voriconazole pharmacokinetics and photosensitivity in children with cystic fibrosis. J Cyst Fibros 2012: 11: 246-252.
45. Glackin L, Leen G, Elnazir B, Greally P,. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J 2009: 102: 29.
46. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005: 4: 215-220.
47. The Drug Information Handbook, 23rd edn. Lexicomp Drug Information 2014, Lexicomp® Mobile Application Version:2.1.0, Lexi-Comp, Inc., Wolters Kluwer Health.